Exploration of predictive factors for prognosis of community-onset pneumonia in adults: a multicenter prospective observational study - Exploration of predictive factors for prognosis of community-onset pneumonia in adults

agasaki University0 sites2,103 target enrollmentNovember 29, 2018

Overview

Phase: 未知
Intervention: Not specified
Conditions: Not specified
Sponsor: agasaki University
Enrollment: 2103
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

November 29, 2018

End Date

December 31, 2021

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

agasaki University

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•\- Any subject who is transferred to a participating medical institution after already being hospitalized for 48 hours or more at any other hospital. \- Hospital acquired pneumonia (ie, develops signs and symptoms of pneumonia after being hospitalized for 48 hours or more) \- Previous enrollment in this study within the past 30 days. \- Any subject who has received effective antibacterial drug therapy for the current pneumonia and improvement is observed (Note: subjects who have received antibacterial agents for a continuous duration of more than 3 days for the current pneumonia and considered as treatment failure based on the investigators judgment are allowed). \- Any subject who has received azithromycin during the previous 7 days. \- Any subject who has a concurrent condition or infection that, in the investigators judgment, would preclude evaluation of therapeutic response (e.g. advanced cancer, primary or metastatic lung cancer, severe heart failure, cystic fibrosis, AIDS, pneumocystis pneumonia, active tuberculosis) \- Any subject who has a history or current condition, therapy, laboratory abnormality, or other circumstance that, in the opinion of the investigator, might confound the results of the study or interfere with the participation for the full duration of the study. Note: Subjects who are anticipated to be treated with any of the following medications during the course of study are allowed: long\-term low\-dose macrolide therapy without change of dosage, intravenous/oral/inhaled prednisolone (\<10 mg/day) without change of dosage, immunosuppressive agents without change of dosage, and antipyretic analgesics taken as a one\-shot\-medicine.